Hydromer Inc (CE) (HYDI) 銘柄情報

No, I sold before it went dark. Peter was a very disappointing CEO. The new leadership seems to be making an effort to get this back on track, I hope they're successful, but I'm not going to go into the dark market for it.

Are you still in this? How do you see this playing out ?

Can this be still traded?

There's still a ton of potential here, glad to see Martin stayed on, he seemed to be the most critical person in the c-suite since his father left.

There should be more opportunities available in the coating business and maybe some good new talent to look at, as Covalon is abandoning their coating business that brought in about a million a year of R&D work and a small royalty stream.

Indeed, refreshing to see some changes

so exciting with all the recent news and change. http://www.nonamestocks.com/2023/09/hydi-new-beginning.html

perhaps the comeback many have been waiting fr has commenced?

I’m excited for this activist group to take charge and clean up this company. There’s millions of value just sitting there being wasted.

https://finance.yahoo.com/news/hydromer-inc-otc-hydi-shareholders-235000049.html

Thanks.
I only invest in shells
Investing in actual businesses is too much risk on the OTC LOL

I look for Custo shells that are getting cleaned up and sold. That’s my cup of tea.

https://www.synergymgtgroup.com/

These business that waited for the final hour to get current are a major red flag., procrastination is an insult to common shareholders holders.

This should have never gone dark to wind up on the Tier change list.
Nothing like watching your stock get sent into the grey sheets to motivate a CEO.,not a good resume builder.

I can see R/M shells getting cleaned up at this final hour, but not a viable business.
This came up on the Tier list a few days back. Made me look.

Just not my cup of tea either..

$HYDI Hydromer, Inc. Surpasses the 40-Year Mark as a World-Wide Supplier of Specialty Coatings for Medical and Industrial Applications and Announces That Its New Facility in North Carolina is Fully Operational With Extensive New Capabilities
Press Release | 09/23/2021
Concord, NC, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Hydromer, Inc. (the “Company”) (HYDI:OTC):

Hydromer, a world-wide supplier of coatings for medical devices and industrial applications, is excited to announce that our brand-new facility with extensive new capabilities is fully operational, marking the proud occasion of serving global customers now for over 40 years. Located in Concord (suburb of Charlotte), North Carolina, our new facility is a fully FDA certified, ISO9001:2015 and ISO13485:2016 approved site, designed per the latest specifications to accommodate all the Company’s functions under one roof, offering the following notable services:

Collaborative research and development (R&D) and manufacturing of coating formulations with production capabilities ranging from initial customer product prototype to scale-up to large quantities, including but not limited to, contract development and supply of custom coatings per customer’s needs.
Coatings that can be heat or UV-cured, in solvent and water base versions to accommodate any type of coating requirements.
Offering a wide range of surface modification processes such as corona, plasma treatment, solvent-cleaning and others, for difficult materials that are becoming the norm in many medical interventional devices such as microcatheters and endoluminal surgeries.
Very large, modular ISO-class 8 clean room to accommodate customers’ devices of various sizes and quantities, including capabilities to coat devices up to 20-FT (600 CM) in length.
Precision coating under magnification for micro-devices with strict tolerances.
Expertise in coating complex devices like balloons, intricate IDs, multi-lumen and others, including emerging 3-D printed parts used in device development.
Extensive analytical capabilities such as Gas Chromatography with Mass Spectroscopy (GC-MS), High Performance Liquid Chromatography (HPLC), Fourier Transmission Infra-Red (FTIR), Spectrophotometers, Contact Angle, Ultra-High resolution video scanning microscope, and other specialized scientific instrumentation.
Extensive testing capabilities, including American Society for Testing and Materials (ASTM), International Organization for Standardization (ISO), The Conformitè Europëenne (CE) and Other standardized methods for friction/pinch force, abrasion resistance, light transmittance, hardness, adhesion, surface tension and others.
Customized coating equipment design services developed in-house and tailored to meet customers’ specific needs.
Quality Assurance offering OQ & PQ validations for customer devices, both new and innovative devices, as well as reprocessed devices, to ensure customer requirements are met.
Our coating formulations marketed under HYDROMER™, LUXERE™, BRILLIANZ™, and GLACIAL™ brands offer highest lubricity, outstanding durability, lowest particulate, fog and frost control, thrombo-resistance, and many other sought-after performances that customers require to differentiate their medical devices and industrial products. Most of our medical grade coatings have FDA MAF files to assist our customers with their regulatory submissions.

“We are proud of our 40-year heritage, proven innovation and remarkable customer service to benefit our smaller and large size customers. We are very excited to add these additional capabilities to continue the journey as a ‘one-stop shop/ full-service provider’ of world-class products and services to customers around the world,” said Peter M. von Dyck, Hydromer CEO.

Hydromer’s legacy of innovation provides many technologies and areas of expertise that are in high demand, from antimicrobial coating capabilities, line of alcohol and plant-based sanitization products, proprietary technologies, including a line of anti-fog and condensation control products; the company expects continual increase in global demand for those products given the current more infection control minded ecosystem.

About Hydromer®

Hydromer®, Inc & Subsidiary (the “Company”) is an ISO 9001:2015 leading global business-to-business (B2B) surface modification and coating solutions provider offering polymer research & development, and manufacturing services capabilities for a wide variety of applications. We are a U.S. public corporation domiciled in Concord, NC. Our customers are located across the United States of America, Europe, and Asia-Pacific. The Company was established in 1980, originally incorporated in the State of New Jersey. Driven by the new corporate leadership’s strategic business objectives and goals, the Company’s operations were restructured into two distinct business segments: industrial and medical. We have successfully developed over 90 proprietary formulations and have secured over 400 patents worldwide at separate times throughout our history including, anti-microbial, anti-fog, anti-frost, condensation-controlling, hydrophilic and thromboresistant coatings. The Company’s track record of innovation plays an integral part in over four decades of sustainable revenues from product sales and services, royalties, and support agreements.

For the latest information about Hydromer, Inc. and its products, please visit our web site at www.hydromer.com or contact us at info@hydromer.com.

Ravi Rangarajan

(908) 722-5000 Ext. 214

rrangarajan@hydromer.com

Attachment

Hydromer, Inc.

Not a shell, Hydromer is still the family business I profiled in the i-box above.

I sold near the end of last year because I was frustrated that financials were so far behind, there was little to no evidence of growth, and financial discipline the father had show. In running this business was clearly thrown to the wayside.

These recent financials aren't much to get excited about, but the new customer win sounds potentially significant.....but I'm content to watch from the outside for now.

Yield sign current today
2m float @ .64
Seems about priced right.
Now what does it do? Shell looking for a story
Who’s putting out the effort?

$HYDI Hydromer Inc. is Pleased to Announce the Addition of a New Global Business Development Manager to Propel Growth
Press Release | 06/29/2021
Concord, NC, June 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Hydromer, Inc. (the “Company”) (HYDI:OTC) is pleased to announce that Mr. Craig Hughes has recently joined the Hydromer family in the capacity of Global Business Development Manager reporting to Ravi Rangarajan, Vice President, Sales & Business Development. Mr. Hughes is a seasoned veteran in the chemical industry with extensive knowledge of Coatings and Adhesives among other products. He has multi-faceted experience gained through Product Development, Sales and Business Development roles at well-known global companies. Craig’s academic background is impressive and includes a Ph.D in Organic Chemistry from the University of Florida and a Post Doctoral Research Fellow at the University of Birmingham UK. His most recent professional background includes the positions of Business Development Manager with EMD Performance Materials Corporation, Sales Development roles with Siltech Corporation and Evonik Corporation, and Business Development and R&D Group Leader positions with Clariant Corporation.

“The addition of this proven industry veteran will further empower Hydromer in taking a more aggressive approach in the vast specialty polymer and surface coatings market. Hydromer is better positioned to expand and grow upon our proven solutions for various applications in the medical and healthcare segments,” said Ravi Rangarajan, VP Sales & Marketing, Hydromer.

Hydromer, Inc. is an innovative ISO 9001:2015 technology-focused company engaged in the business of inventing, developing, patenting, licensing, manufacturing and selling hydrophilic polymer-based Coatings for Medical Device, Health Care, and Industrial market segments. Hydromer also provides highly specialized medical coating services and coating equipment, is FDA registered and ISO 13485 & ISO9001 certified.

For the latest information about Hydromer, Inc. and its products, please visit our web site at www.hydromer.com

Ravi Rangarajan

(908) 722-5000 Ext. 214

rrangarajan@hydromer.com

Not sure why N8 Endotracheal tube program doesn't seam to have advanced.
I guess the Canadian EUA still stands, but not like we'll get to see if makes any difference to HYDI financials.

Gave up holding this company, despite how much I like their business, they'll never move up market and get attention from more serious investors with their erratic financial reporting over the past few years.

Hydromer Inc Signs Agreement to Sell Their Hand and Surface Sanitizer Lines, Hydromer First Responder, HydroProtect and EscenciaProtect on the stockd e-Commerce Marketplace
Press Release | 12/03/2020
Concord, NC, Dec. 03, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Hydromer Inc (HYDI:OTC) has signed an agreement to sell their Hydromer® First Responder® and HydroProtect® liquid and gel sanitizer lines and coming soon their EscenciaProtect® plant-based sanitizer line on stockd®, an e-Commerce marketplace powered by Premier, a leading healthcare improvement company with more than three decades of healthcare purchasing expertise. Effective 10/20/2020, the agreement allows Hydromer® to make products available for purchase on the stockd marketplace.

Hydromer® will feature their sanitizer lines which include, Hydromer® FirstResponder®, a hospital strong liquid formulation that is 80% v/v denatured ethyl alcohol that kills up to 99.9% of germs, including COVID-19, HydroProtect® gel sanitizer line that is 75% v/v denatured ethyl alcohol, with aloe vera for soothing hands, and proven to kill 99.9% of germs, and EscenciaProtect® which is a patented, “non-alcohol”, plant-based sanitizer line that provides many benefits over the traditional alcohol-based products, including a barrier of soothing moisturizer that protects your hands from harmful germs and bacteria for up to one hour without re-applying, killing many germs including MRSA, Candida Auris, and COVID-19, on the stockd marketplace. Additionally, the stockd marketplace will feature a Hydromer® brand shop at Hydromer’s Shop.

“Hydromer is very excited to be partnering with Premier Inc’s stockd, a leading online marketplace, to provide our highest quality and highly-in demand sanitizing solutions in the fight against the COVID-19 pandemic to a wide variety of clients,” stated Ravi Rangarajan - VP of Sales And Marketing.

stockd® is an online marketplace that connects sellers to buyers. Built by and for healthcare professionals, the stockd marketplace is powered by Premier, a leading healthcare improvement company that unites an alliance of more than 4,000 U.S. hospitals and health systems and approximately 175,000 other providers and organizations to transform healthcare. Harnessing the experience, relationships, and innovative technology of Premier—along with the knowledge of the healthcare community— the stockd marketplace provides an exceptional digital purchasing experience complete with tools and insights to help businesses thrive. Learn more at www.stockd.com.

ABOUT HYDROMER®

We are actively engaged in the fight against COVID-19 pandemic by manufacturing various products that aid in helping save lives, including our antimicrobial anti-fog coatings for PPE, our antimicrobial hydrophilic coatings for medical devices and our sanitizing product line. We are making our alcohol sanitizer products and our patented non-alcohol sanitizers, available under our Hydromer® First Responder® (FDA Registered), HydroProtect® or EscenciaProtect® brands or privately labeled under your own brand to ensure getting these important products, quickly available to end users during the current status of high demand amidst stricter FDA controls. We have pledged to donate hand sanitizer to local first responders with every order.

Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs.

We are a leader in?developing coating formulas and processes that meet a market-driven need for greener, more sustainable solutions. We also offer contract coating services, customized coating equipment, contract manufacturing, and turnkey operations backed by outstanding teams of research and development, customer service, and tech support. We are an FDA, GMP/ISO 13485, and ISO 9001 production facility.

Hydromer
800-287-5208
info@hydromer.com

Hydromer's Plant Based Sanitizers Show Significant Reduction of COVID-19 Virus and Many Other Microbes

Concord, NC, Sept. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Hydromer, Inc. (OTC:HYDI) or “the Company” announced today that its plant-based EscenciaProtect™ line of sanitizing products showed significant reduction in growth of COVID-19 virus in recent testing done by the external “Institute for Antiviral Research” lab at the University of Utah.

The testing shows statistically significant reduction in the growth of the COVID-19 virus when exposed to Hydromer’s plant-based sanitizer formulations. The study showed that “tested neat and at dilutions at 15-minute and 1-hour contact time intervals, the test samples exhibited virucidal activity, reducing SARS-CoV-2 below the limit of detection resulting in Log Reduction Values of >2.5 (>99%) and >3.5 (>99.9%). Neutral controls did not inhibit virus growth and did not exhibit cytotoxicity.”

Previous testing done by other external labs have shown these products to also be effective against a variety of other microbes including NoroVirus, MRSA, Salmonella, E-Coli and others, validating that Hydromer’s EscenciaProtect™ line has broad-spectrum sanitizing capabilities.


“Hydromer is very proud to have one of the first greener alternatives to alcohol-based sanitizers, now tested and available in the global response to the COVID-19 pandemic. With so many segments of the market desperate for alcohol-free product, such as schools, retail, airlines and more, we recognized how critical it was to test our proprietary technology against this specific virus. We are very pleased to be in a position now to supply a much-needed alternative to the growing market of sanitizers,” said Peter M. von Dyck, Hydromer CEO.

In addition, with performance features such as plant-based, natural, longer lasting moisturization, non-flammable and many others, Hydromer’s patented EscenciaProtect™ line offers a very compelling non-alcohol solution for various sanitation needs. The line is being offered in various formulation formats such as ready-to-use sanitizer, sprayable liquid, ready-to-use hand soap, concentrate additive for formulation, and others. Hydromer looks forward to partnerships and distribution opportunities with other companies to take this unique technology into the hands of end users for various sanitation needs across various market segments.

About Hydromer

We are actively engaged in the fight against COVID-19 pandemic by manufacturing various products that aid in helping save lives, including our anti-fog coatings for PPE, our anti-microbial hydrophilic coatings for medical devices and our sanitizing product line. We are making our alcohol sanitizers per approved guidelines of FDA and also registered with FDA, and non-alcohol sanitizer products, available under our Hydromer First Responder™, HydroProtect™ or EscenciaProtect™ brands or privately labeled under your own brand to ensure getting these important products quickly available to end users during the current status of high demand amidst stricter FDA controls.

Hydromer, Inc.

800-287-5208

info@hydromer.com

N8 Medical Announces its CeraShield™ Coating inhibits COVID-19 Virus Growth on Endotracheal Tubes

https://www.einnews.com/pr_news/523679070/n8-medical-announces-its-cerashield-coating-inhibits-covid-19-virus-growth-on-endotracheal-tubes

NEWS PROVIDED BY
N8 Medical
August 11, 2020, 12:45 GMT

Photo of endotracheal tube extubated from patient with COVID-19. Green coloration of the tube is indicative of extensive bacterial fouling.

Reduction in COVID-19 Virus Exposure May Benefit Patients, Doctors and Nurses

DUBLIN, OHIO, UNITED STATES, August 11, 2020 /EINPresswire.com/ -- N8 Medical, LLC, a privately held biotechnology company, today announced that its CeraShield™ coated endotracheal tubes significantly reduced the growth of COVID-19 virus in recent testing. The testing shows statistically significant reduction in the growth of the COVID-19 virus on the tube surface in 60 minutes. Ordinary uncoated endotracheal tubes either allowed increased virus growth or had no inhibitory effect.

“Recent COVID-19 research has shown that the virus is able to adhere to plastic surfaces and is also able to be aerosolized and inhaled by people in close proximity, including doctors and nurses” says Ronald Bracken, President and Chief Operating Officer of N8. Mr. Bracken added “Most endotracheal tubes are made of plastic. COVID-19 patients who become mechanically ventilated will require use of one of these plastic tubes to connect to the mechanical ventilator.”

Ordinary endotracheal tubes lack any antifouling protection. Within hours, these tubes become breeding grounds for biofilms, pathogenic bacteria, fungi and viruses. This often leads to deadly secondary infections that can be multidrug resistant, and other complications.

Dr. Michael Niederman, a leading expert in respiratory infections and a member of N8 Medical’s Scientific Advisory Board stated “Anything that can significantly reduce the presence of pathogens on the surface of an endotracheal tube is a welcome advance that has the potential to reduce a patient’s length of stay, reduce antibiotic and drug use and improve patient’s outcomes. I look forward to the results of clinical studies to evaluate the magnitude of the potential benefit of the CeraShield™ endotracheal tube in COVID-19 patients.”

N8 Medical has previously completed first-in-human clinical trials in non-COVID, mechanically ventilated patients with no adverse effects. Those clinical studies have shown that the CeraShield™ endotracheal tubes were able to completely prevent pathogenic bacterial and fungal biofilm growth of tube surfaces.

A leading market research firm recently awarded N8 Medical’s CeraShield™ endotracheal tube “Product Innovation of the Year” award for its CeraShield™ technology platform for prevention of hospital-acquired infections. FDA has designated the CeraShield™ endotracheal tube as a “breakthrough device.”

The company previously announced that Health Canada has granted Emergency Use Authorization for use of the CeraShield™ endotracheal tube in COVID-19 patients who require mechanical ventilation in Canada. The Company has pending EUA request with the FDA and with the MHRA in the UK. Clinical studies are currently planned in COVID-19 hotspots. Hospitals that have an interest in participating in clinical studies are encouraged to contact N8 Medical at covid@n8medical.com.

ABOUT N8 MEDICAL

N8 Medical, LLC (www.N8Medical.com), headquartered in Dublin, Ohio, is a rapidly-growing, privately-held clinical stage biotechnology company developing a platform of anti-fouling medical devices designed to have significant, life-saving clinical impact through reduction of infection, related complications and mortality. Key publications are available at www.N8Medical.com.

Interesting post on LinkedIn:

The company's customer, N8 Medical, just posted on LinkedIn that their Ceradhield coated endotracheal tube was tested and shown to inhibit the growth of SARS-COV2 and has a pending EUA Application with the FDA.

https://www.linkedin.com/posts/hydromer-inc._cerashield-coating-inhibits-covid-19-virus-activity-6696837744523563008-DPPi

$HYDI Hydromer, Inc Files 2019 Annual Report and Fiscal Year 2020 Non-Audited Interim Financial Update
Press Release | 07/07/2020
Concord, NC, July 07, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hydromer, Inc (OTCMKTS: HYDI), a leading global manufacturer of custom industrial and medical device surface modification technologies, announced today that it has filed the company’s annual report and accompanying financial results for the full fiscal year ended on June 30, 2019 with the OTC Markets. The company has also posted its interim financial update on the company’s website. The fiscal year 2020 financial update presents un-audited interim financial information corresponding to the period ended May 31 of Fiscal Year 2020. The 2020 interim financial update is uploaded to Hydromer’s website at https://www.hydromer.com/investor-relations/. The 2019 annual report and the shareholder report may be accessed directly from the OTC Markets website at https://www.otcmarkets.com/stock/HYDI/disclosure, is also available on Hydromer Investors Relations website at https://www.hydromer.com/investor-relations/.

Hydromer’s legacy of innovation provides many technologies and areas of expertise that are in high demand, from antimicrobial coating capabilities, line of alcohol and plant-based sanitization products, proprietary technologies, including a line of anti-fog and condensation control products; the company expects continual increase in global demand for those products given the current more infection control minded ecosystem.

About Hydromer® www.hydromer.com
As a globally trusted partner to companies of all sizes, Hydromer® has been offering specialty polymers and surface coating technologies, contract coating services, and custom-designed equipment for diverse applications since 1981. Hydromer’s leading-edge solutions amplify products within many industries, including medical devices, industrial plastics, biotechnology, aerospace and personal care. Hydromer® personifies innovation, driven by a team of exceptional Ph.D. chemists and innovators, offering outstanding R&D, customer service, and tech support. The company continually focuses on the future by developing innovative solutions comprised of more eco-friendly and sustainable approaches. Hydromer® is an FDA registered, ISO 13485:2016 and ISO 9001:2015 certified production facility.

Hydromer, Inc.
800-208-0314
Info@hydromer.com

They are definitely testing my patience, on one hand their business execution seems to be going great with the pivot to manufacturing hand sanitizer, securing a contract to supply the N8 Endotracheal tubes, and even getting a meeting with congressmen and Secretary of Commerce, as posted on their LinkedIn.

On the other hand, I just want to see some current financials and see how much of their cash pile was used up with the move and modernization of their manufacturing facilities. I bet this stock would be a couple dollars higher, even if those financials showed they burned through the cash and were about break even with operations.....but no one knows....it takes trust.....and I trust the kids want to make their Dad proud with their innovation and leadership.....but show us some recent numbers....PLEASE!

Great find but unfortunately ( almost tragically) metaphorically I washed my hands of the whole thing!!!!

N8 plans to continue to seek emergency use authorizations in other countries.

Health Canada expands emergency use of the CeraShield™ Endotracheal Tube to all hospitals in Canada

NEWS PROVIDED BY

N8 Medical, LLC
Apr 23, 2020, 13:47 ET

May help prevent deadly ventilator-associated bacterial infections and complications in COVID-19 patients

DUBLIN, Ohio, April 23, 2020 /PRNewswire/ -- N8 Medical, LLC (N8) today announced that Health Canada has granted emergency use access marketing approval of the company's CeraShield™ Endotracheal Tube for all Canadian mechanically-ventilated COVID-19 patients. FDA has previously designated the CeraShield ETT as a "breakthrough" device. N8 plans to continue to seek emergency use authorizations in other countries.

N8's CeraShield™ tube has a patented anti-fouling coating designed to prevent deadly bacterial infections that frequently occur in ventilated patients. Conventional endotracheal tubes allow pathogenic bacteria to rapidly grow on the tube surfaces and are a source of infection that may lead to acute kidney injury, sepsis and death.

"There is growing concern over the reported high death rates among mechanically ventilated COVID-19 patients. Death rates as high as 50% in China and 80% in New York have been reported. Patients infected with the COVID-19 virus who require mechanical ventilation are highly susceptible to exposure to bacterial pathogens and ventilation complications. The coating on the CeraShield tube prevents the formation of biofilms that routinely foul the plastic surfaces of unprotected conventional endotracheal tubes and lead to bacteria growth," said Carl Genberg, N8's Chief Scientific Officer.

"N8's CeraShield™ Endotracheal Tube may reduce secondary bacterial infections, save lives and expand ventilator resource capacity by getting patients off ventilators sooner," said Ronald Bracken, N8's President and Chief Operating Officer. "We are pleased that Health Canada is now allowing all hospitals to have access to this potentially life-saving technology."

If you are a Canadian clinician or facility desiring to access CeraShield™ Endotracheal Tubes, please contact the company promptly at covid@n8medical.com as supplies are currently limited.

N8 has partnered with Hydromer Inc. (www.hydromer.com) and its wholly owned subsidiary and med-tech division, Biosearch Medical Products, Inc., in connection with material supply and production of the CeraShield™ Endotracheal Tubes for this important effort.

ABOUT N8 MEDICAL
N8 Medical, LLC (www.N8Medical.com), headquartered in Dublin, Ohio, is a rapidly-growing, privately-held clinical stage biotechnology company developing a platform of anti-fouling medical devices designed to have significant, life-saving clinical impact through reduction of infection, related complications and mortality. Key publications are available at www.N8Medical.com.

CAUTION: In United States, the CeraShield™ Endotracheal Tube is investigational and has not been granted marketing approval. These statements have not been evaluated by Health Canada or FDA.

SOURCE N8 Medical, LLC


Related Links
http://www.n8medical.com

Next pr we will see a distributing deal inked. Love this company

Yes very key!! Secondary infection is so rampant right now. Getting the word out about our CeraShield is happening in front of our eyes

Key point here is that Health Canada's Emergency Use authorization now extends across all of Canada, where as N8's April 2nd PR indicated "that Health Canada has granted Dr. John Muscedere of Kingston General Hospital's emergency request to begin using the N8 Medical CeraShield™ Endotracheal Tubes in mechanically-ventilated COVID-19 patients."



Hydromer and N8 Medical Partner to Bring Life-Saving Coated ET Tubes for COVID-19 Patients

GlobeNewswire

April 24, 2020

CONCORD, NC, April 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Hydromer (OTCQB: HYDI) announced today that it will be the exclusive coating supplier and manufacturing partner for N8 Medical’s CeraShield™ Endotracheal Tube. Health Canada has granted emergency use access marketing approval for the CeraShield™ Endotracheal Tube for all Canadian mechanically-ventilated COVID-19 patients.

N8's CeraShield™ tube has a patented anti-fouling coating to prevent deadly bacterial infections that frequently occur in ventilated patients. Conventional endotracheal tubes allow pathogenic bacteria to rapidly grow on the tube surfaces and are a source of infection that may lead to acute kidney injury, sepsis and death.

“N8’s CeraShield™ Endotracheal Tube may reduce secondary bacterial infections, save lives and expand ventilator resource capacity by getting patients off ventilators sooner,” said Ronald Bracken, N8’s President and Chief Operating Officer. “We are pleased that Health Canada is now allowing all hospitals to have access to this potentially life-saving technology.”

CAUTION: In the United States, the CeraShield™ Endotracheal Tube is investigational and has not been granted marketing approval. These statements have not been evaluated by Health Canada or FDA.

About Hydromer® www.hydromer.com

Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs. Hydromer is also manufacturing their own brand of hand sanitizer under the First Responder™ brand.

About N8 Medical www.n8medical.com

N8 Medical, LLC (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.

If you have an interest in coating your devices or the CeraShield™ endotracheal tubes, please contact us right away!

Email us at info@hydromer.com Or call us at 800-326-5976.

Hydromer and N8 Medical Partner to Bring Life-Saving Coated ET Tubes for COVID-19 Patients
GlobeNewswireApril 24, 2020, 12:43 PM PDT
CONCORD, NC, April 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Hydromer (OTCQB: HYDI) announced today that it will be the exclusive coating supplier and manufacturing partner for N8 Medical’s CeraShield™ Endotracheal Tube. Health Canada has granted emergency use access marketing approval for the CeraShield™ Endotracheal Tube for all Canadian mechanically-ventilated COVID-19 patients.

N8's CeraShield™ tube has a patented anti-fouling coating to prevent deadly bacterial infections that frequently occur in ventilated patients. Conventional endotracheal tubes allow pathogenic bacteria to rapidly grow on the tube surfaces and are a source of infection that may lead to acute kidney injury, sepsis and death.

“N8’s CeraShield™ Endotracheal Tube may reduce secondary bacterial infections, save lives and expand ventilator resource capacity by getting patients off ventilators sooner,” said Ronald Bracken, N8’s President and Chief Operating Officer. “We are pleased that Health Canada is now allowing all hospitals to have access to this potentially life-saving technology.

News

1.60/2.00 contracts coming, covid disinfecting products

19,800 bid 1.50

Break 1.70 and we move to the 3’s

9,900 bid 1.50

1.69 up

Bid 9,700 1.45

Bid building 4K at 1.36, confirmation on there product getting released will send this to 10 plus bucks

8 followers

Hydromer® First Responder™ Hand Sanitation Solutions

Hydromer is actively engaged in the fight against COVID-19 by scaling up manufacturing of our various hand sanitizers during the current extreme demand and short supply of those critical products. Hydromer offers a variety of sanitizer solutions, including a US FDA mandated “alcohol-based” sanitizer version, which is widely needed across the entire spectrum of healthcare, safety, first response and many other critical functions. We are actively seeking partnerships, suppliers and sources of alcohol to ensure a steady supply of hand sanitizers, to the healthcare market. We have also secured a special permit from the ATF (Bureau of Alcohol, Tobacco, Firearms).

COVID in play here two items moving forward

52% of the 4.7 million OS is held by two insiders


https://backend.otcmarkets.com/otcapi/company/financial-report/241465/content

Great video

Huge volume for this ticker

1.28 getting taken out

This is getting ready to fly

Bought 1,200 shares today

HYDI partner news: Health Canada Grants Emergency Use Authorization for N8 Medical CeraShield™ Endotracheal Tubes in Mechanically Ventilated COVID-19 Patients
Evaluating potential for reduction of secondary bacterial infections and mechanical ventilation days to improve patient outcomes and optimize use of scarce ventilators

N8 Medical, LLC Logo (PRNewsfoto/N8 Medical, LLC)
NEWS PROVIDED BY

N8 Medical, LLC
Apr 02, 2020, 09:55 ET

DUBLIN, Ohio, April 2, 2020 /PRNewswire/ -- N8 Medical, LLC (N8 Medical) today announced that Health Canada has granted Dr. John Muscedere of Kingston General Hospital's emergency request to begin using the N8 Medical CeraShield™ Endotracheal Tubes in mechanically-ventilated COVID-19 patients.

N8 Medical's CeraShield™ Endotracheal Tube has a patented anti-fouling coating that is designed to prevent deadly bacterial infections that frequently occur in ventilated patients with respiratory viral infections. In contrast, conventional endotracheal tubes allow pathogenic bacteria to grow on the tube surfaces within hours and form slime-like aggregations of millions of pathogenic cells as a biofilm. In the 1918 influenza pandemic, 95% of influenza patient deaths were caused by secondary bacterial infections. Bacterial infections are a major source of mortality among ICU patients. According to recently published reports, the mortality in COVID-19 patients requiring advanced respiratory support (ventilators) ranges from 66% to 86%. N8 Medical believes that use of the CeraShield™ Endotracheal Tube may reduce this rate of mortality.

"Biofilm growth on endotracheal tubes may lead to deadly secondary bacterial infections and exaggerated inflammatory responses requiring 8 to 9 days of additional mechanical ventilation. Preventing virally-infected patient exposure to bacterial biofilms on the endotracheal tube is critically important," said Carl Genberg, N8 Medical's Chief Scientific Officer. "In a time of severe shortage of mechanical ventilators, we believe that use of the CeraShield™ Endotracheal Tube has the potential to both reduce mortality and optimize ventilator capacity by getting patients off the ventilator sooner. We thank Dr. Muscedere for his efforts to secure use of the CeraShield™ Endotracheal Tube and the Canadian Government for granting his emergency request," said Carl Genberg, N8 Medical's Chief Scientific Officer.

Frost & Sullivan recently issued its Product Innovation of the Year Award to N8 Medical for its platform technology designed to prevent hospital acquired infections. FDA has designated the CeraShield™ Endotracheal Tube as a "breakthrough device" pursuant to the 21st Century Cures Act. The device is currently an investigational product.

Dr Muscedere is an Intensivist at Kingston General Hospital, and Co-Chair of the Canadian Critical Care Trials Group (CCCTG) Knowledge Translation Committee. Dr. Muscedere was the Principal Investigator in a clinical feasibility study of the CeraShield™ Endotracheal Tube of ten patients at Kingston General who were intubated with the CeraShield™ Endotracheal Tube. That study indicated that use of the CeraShield™ Endotracheal Tube does not have adverse side effects and was able to prevent dangerous pathogenic bacteria from growing on the tube and in endotracheal tube aspirates.

N8 medical is currently in discussions with other physicians regarding emergency use during this ventilator resource-straining pandemic.

ABOUT N8 MEDICAL
N8 Medical, LLC (www.N8Medical.com), headquartered in Dublin, Ohio, is a rapidly-growing, privately-held biotechnology company developing a platform of anti-fouling medical devices designed to have significant, life-saving clinical impact through reduction of infection, related complications and mortality. N8 Medical's CeraShield™ technology is based upon novel compounds called ceragenins (also referred to as CSAs). There are over 90 peer-reviewed journal articles regarding the ceragenin technology, which was invented by Professor Paul B. Savage, Professor of Chemistry and Biochemistry at Brigham Young University (Provo, UT). Key publications are available at www.N8Medical.com.

CAUTION: In Canada and the United States, the CeraShield™ Endotracheal Tube and has not been granted marketing approval. These statements have not been evaluated by Health Canada or FDA.

SOURCE N8 Medical, LLC


Related Links
http://www.n8medical.com

Hydromer mentions their antimicrobial coatings in that headline, but not in the news.

This news from N8 Medical is from December, sounds like we could there's potential for more interesting news soon:
https://www.mddionline.com/can-breakthrough-medical-device-reduce-risk-hospital-associated-infections

Nice news!

been watching this one for a month or two now. Took a position last week. One day the explosion here is going to be epic. DD is amazing here.

Hydromer Inc. Now Active in the COVID-19 Emergency Response with Availability of its Sanitizers and Antimicrobial Coatings
GlobeNewswireMarch 26, 2020

Concord, NC, March 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hydromer, Inc. (“Hydromer®” or the “Company”) (OTCQB: HYDI) announced today that it is actively engaged in the fight against COVID-19 by immediately scaling up manufacturing of its various hand sanitizers during the current extreme demand and short supply of those critical products. Hydromer is commercializing a variety of sanitizer solutions, including a US FDA & World Health Organization-mandated “alcohol-based” sanitizer version, which is widely needed across the entire spectrum of healthcare, safety, first response and many other critical functions. Hydromer is also rejuvenating its patented “non-alcohol”, plant-based sanitizing and cleaning product line that can provide enhanced benefits over the traditional alcohol-based products. During the current epidemic and COVID-19 outbreak, Hydromer is working with private and public sector entities, including various State and Local government organizations to supply first responders and essential workers with much needed sanitizing products.  

“Hand sanitizers are in incredible demand and although the regulations to manufacture them are in some cases temporarily being eased to address the current massive shortage of alcohol, we also see the World Health Organization (WHO) and the FDA seeking to tighten up specifications to ensure quality and authenticity in the labeling and the proper use of ingredients at the right levels,” said Martin von Dyck, Chief Operating Officer (COO).  “With this in mind, we see that Hydromer’s 40 year track record, as an FDA certified facility and maker of innovative medical technologies for products that serve the Intensive Care Units and nursing homes will bring precision, credibility, and alternatives to those within this emergency response and with future outbreaks,” said Peter M. von Dyck, Chief Executive Officer (CEO). 

Hydromer is actively seeking partnerships, suppliers and sources of alcohol to ensure a steady supply of hand sanitizers, to the healthcare market. Hydromer has also secured a special permit from the ATF (Bureau of Alcohol, Tobacco, Firearms). As an essential business worker and qualified healthcare ICU/emergency response support provider, Hydromer continues its manufacturing operations to supply its regular customers with much needed healthcare, ICU and emergency care products during this time of great need.

Hydromer, Inc. is an innovative ISO 9001:2015 technology-focused company engaged in the business of inventing, developing, patenting, licensing, manufacturing and selling hydrophilic polymer-based products for commercial markets including Medical Device, Pharmaceutical, Biotechnology, Industrial Plastics, Cosmetic and Personal Care. Hydromer also provides highly specialized medical coating services to industry through its FDA registered and ISO 13485:2016 certified Medical Products subsidiary. For the latest information about Hydromer, Inc. and its products, please visit our web site at www.hydromer.com
Or contact us now via phone or email

Hydromer Inc.
1-800-287-5208
Info@hydromer.com